Development of cancer medicine at a reduced dose by use of modern technologies (Q78546): Difference between revisions
Jump to navigation
Jump to search
(Changed an Item: Label in wikidata changed) |
(Created claim: summary (P836): The project will result in a novel medicine containing apbitterone acetate with increased bioavailability in relation to the reference medicine — Zytiga & ndash;Janssen-Cilag.Obtaining such a product will require the use of modern technologies and advanced R & D. the project will develop a significantly improved medicine, containing a lower dose of the active substance, which will help to improve patient safety resulting from the reduction of ad...) |
||
| Property / summary | |||
The project will result in a novel medicine containing apbitterone acetate with increased bioavailability in relation to the reference medicine — Zytiga & ndash;Janssen-Cilag.Obtaining such a product will require the use of modern technologies and advanced R & D. the project will develop a significantly improved medicine, containing a lower dose of the active substance, which will help to improve patient safety resulting from the reduction of adverse events (e.g. by the gastrointestinal system).The comfort of the sick who will be able to accept 1 or 2 tablets (respectively 250 or 500 mg respectively) will also increase the comfort of the sick/capsule/capsule equivalent to or 4 mg respectively.The effect of Admed’s will also increase the level of use of patients for the prescription of the doctor, as well as the cost optimisation of the therapy for the patient and the payer.The target audience of the project is adult men suffering from opportunistic tumours of the prostate (mCRPC).In 2016, there were 4.452.307 men in the 7-2016 group diagnosed with prostate cancer in the decade 2006-398.624.In Poland, the prostate cancer is the second most important cancer in men.These cancers have increased around five times in the last 3 decades, reaching 12.343 cases in 2014.The achievement of the project’s objective will result from the implementation of 6 work stages of the B + work.1, 3 and 5), which will be corrected on the basis of the results of their use of pharmacokinetic studies (Stage:2 and 4).F (English) | |||
| Property / summary: The project will result in a novel medicine containing apbitterone acetate with increased bioavailability in relation to the reference medicine — Zytiga & ndash;Janssen-Cilag.Obtaining such a product will require the use of modern technologies and advanced R & D. the project will develop a significantly improved medicine, containing a lower dose of the active substance, which will help to improve patient safety resulting from the reduction of adverse events (e.g. by the gastrointestinal system).The comfort of the sick who will be able to accept 1 or 2 tablets (respectively 250 or 500 mg respectively) will also increase the comfort of the sick/capsule/capsule equivalent to or 4 mg respectively.The effect of Admed’s will also increase the level of use of patients for the prescription of the doctor, as well as the cost optimisation of the therapy for the patient and the payer.The target audience of the project is adult men suffering from opportunistic tumours of the prostate (mCRPC).In 2016, there were 4.452.307 men in the 7-2016 group diagnosed with prostate cancer in the decade 2006-398.624.In Poland, the prostate cancer is the second most important cancer in men.These cancers have increased around five times in the last 3 decades, reaching 12.343 cases in 2014.The achievement of the project’s objective will result from the implementation of 6 work stages of the B + work.1, 3 and 5), which will be corrected on the basis of the results of their use of pharmacokinetic studies (Stage:2 and 4).F (English) / rank | |||
Normal rank | |||
Revision as of 09:22, 4 March 2020
Project in Poland financed by DG Regio
| Language | Label | Description | Also known as |
|---|---|---|---|
| English | Development of cancer medicine at a reduced dose by use of modern technologies |
Project in Poland financed by DG Regio |
Statements
7,903,957.62 zloty
0 references
13,559,614.58 zloty
0 references
58.29 percent
0 references
2 January 2018
0 references
30 September 2022
0 references
ADAMED SP. Z O.O.
0 references
51°39'58.3"N, 19°21'33.5"E
0 references
Rezultatem projektu będzie nowatorski lek zawierający octan abirateronu o zwiększonej dostępności biologicznej względem leku referencyjnego - Zytiga – firmy Janssen-Cilag. Uzyskanie takiego produktu będzie wymagało zastosowania nowoczesnych technologii i zaawansowanych prac B+R. W projekcie opracowany zostanie znacząco ulepszony lek, zawierający niższą dawkę substancji czynnej, co przyczyni się do poprawy bezpieczeństwa pacjenta wynikającej ze zmniejszenia liczby zdarzeń niepożądanych (m.in. ze strony układu pokarmowego). Wzrośnie również komfort chorych, którzy zamiast jednorazowego przyjmowania 4 lub 2 tabletek (odpowiednio po 250 lub 500mg) będą mogli przyjąć 1 równocenną terapeutycznie tabletkę/kapsułkę. Efektem udostępnienia leku Adamed będzie również wzrost poziomu stosowania się pacjentów do zaleceń lekarza, jak również optymalizacja kosztowa terapii dla pacjenta jak i płatnika. Zakładaną grupę odbiorców projektu stanowią dorośli mężczyźni cierpiący na oporny na kastrację nowotwór gruczołu krokowego z przerzutami (mCRPC). W 2016 r. w grupie państw 7MM żyło 4.452.307 mężczyzn, u których w dekadzie 2006-2016 zdiagnozowano nowotwór prostaty, z czego u 398.624 chorych był to mCRPC. W Polsce nowotwór gruczołu krokowego jest drugim co do częstości nowotworem u mężczyzn, stanowiąc ponad 15% ogółu zachorowań. Zapadalność na te nowotwory wzrosła ok. pięciokrotnie w ostatnich 3 dekadach, osiągając w 2014 r. 12.343 przypadków. Osiągnięcie celu projektu nastąpi w efekcie realizacji 6 Etapów prac B+R. Ich układ zakłada opracowywanie coraz to doskonalszych formulacji leku z abirateronem w kolejnych etapach badań przemysłowych (Etapy: 1, 3 i 5), które będą poprawiane w oparciu o wyniki uzyskane z przeprowadzonych z ich użyciem badań farmakokinetycznych (Etapy: 2 i 4). F (Polish)
0 references
The project will result in a novel medicine containing apbitterone acetate with increased bioavailability in relation to the reference medicine — Zytiga & ndash;Janssen-Cilag.Obtaining such a product will require the use of modern technologies and advanced R & D. the project will develop a significantly improved medicine, containing a lower dose of the active substance, which will help to improve patient safety resulting from the reduction of adverse events (e.g. by the gastrointestinal system).The comfort of the sick who will be able to accept 1 or 2 tablets (respectively 250 or 500 mg respectively) will also increase the comfort of the sick/capsule/capsule equivalent to or 4 mg respectively.The effect of Admed’s will also increase the level of use of patients for the prescription of the doctor, as well as the cost optimisation of the therapy for the patient and the payer.The target audience of the project is adult men suffering from opportunistic tumours of the prostate (mCRPC).In 2016, there were 4.452.307 men in the 7-2016 group diagnosed with prostate cancer in the decade 2006-398.624.In Poland, the prostate cancer is the second most important cancer in men.These cancers have increased around five times in the last 3 decades, reaching 12.343 cases in 2014.The achievement of the project’s objective will result from the implementation of 6 work stages of the B + work.1, 3 and 5), which will be corrected on the basis of the results of their use of pharmacokinetic studies (Stage:2 and 4).F (English)
0 references
Identifiers
POIR.01.01.01-00-1025/17
0 references